Osteoporosis Treatment Alternatives to Fosamax

First-Line Bisphosphonate Alternatives

The American College of Physicians recommends risedronate and zoledronic acid as equally effective first-line alternatives to alendronate for initial treatment, demonstrating comparable efficacy in reducing fracture risk 1
Risedronate is available as 5 mg daily, 35 mg weekly, 75 mg on two consecutive days monthly, or 150 mg monthly, with high-certainty evidence of reducing vertebral, nonvertebral, and hip fractures 2
Zoledronic acid is administered as 5 mg intravenously every year for treatment or every 2 years for prevention, with high-certainty evidence of reducing vertebral, nonvertebral, and hip fractures 2
All three bisphosphonates (alendronate, risedronate, zoledronic acid) reduce vertebral, nonvertebral, and hip fractures with high-certainty evidence, according to the American College of Physicians 1, 3

Denosumab (60 mg subcutaneously every 6 months) is recommended as second-line therapy when bisphosphonates are contraindicated or cause adverse effects, with moderate-certainty evidence for postmenopausal women and low-certainty evidence for men, as stated by the American College of Physicians 1
Denosumab demonstrates favorable long-term net benefit in postmenopausal women with osteoporosis, prior fractures, and previous bisphosphonate treatment, according to the American College of Physicians 1
If denosumab is discontinued for more than 6 months, bisphosphonate treatment (e.g., zoledronic acid) must be initiated to suppress rebound osteolysis, as recommended by the American Society of Clinical Oncology 4

Raloxifene (60 mg daily) can be considered as initial treatment specifically in younger postmenopausal women, but it reduces only radiographic vertebral fractures, not hip or nonvertebral fractures, and is associated with serious harm risk, including thromboembolism, as noted by the American College of Physicians 2, 3
The American College of Physicians recommends against using raloxifene for osteoporosis treatment due to the harm-benefit profile 3

Teriparatide (20 mcg subcutaneously daily) is reserved for patients with severe osteoporosis or those who have already sustained fractures, reducing vertebral and nonvertebral fractures, as recommended by the American Academy of Family Physicians 2, 3
Teriparatide is typically used only after bisphosphonate failure or in very high-risk patients, according to the American Academy of Family Physicians 2

All patients must receive calcium 1,000-1,200 mg daily and vitamin D 600-800 IU daily, with target serum 25(OH)D level ≥30 ng/mL, as an essential component of any osteoporosis treatment regimen, recommended by the National Osteoporosis Foundation 5

Dental examination must be completed, with invasive dental procedures finished before starting treatment, as recommended by the American Dental Association 4, 5
Serum creatinine and creatinine clearance must be checked—intravenous bisphosphonates are generally not recommended if creatinine clearance <30 mL/min, according to the National Kidney Foundation 5
Fracture risk stratification is mandatory using BMD T-score and FRAX calculation to ensure treatment is appropriate, as recommended by the National Osteoporosis Foundation 5